Clinical trial · Observational
Outcomes and Prognostic Factors in Hepatopancreatoduodenectomy
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
1. In biliary tract malignancies, achieving a microscopically clear resection margin (R0) is considered the only treatment for a cure. 2. Hepatopancreatoduodenectomy(HPD) has been considered a surgical option for patients with extensive bile duct or gallbladder cancer to achieve an R0 resection. 3. The associated high morbidity and mortality rates have prevented HPD from becoming a standard surgical procedure worldwide. 4. Over the past few decades, the understanding of the bile duct anatomy has significantly improved, and many methods have been developed to assess liver function and future remnant liver volume. 5. We aimed to evaluate the short- and long-term outcomes of HPD and to assess risk factors associated with survival, early recurrence, and major complications to better evaluate the potential of the procedure as a standard treatment.
Conditions
Conditions (5)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Bile Duct Cancer | Malignant Bile Duct Neoplasm | CURATED_BROADER | 0.80 |
| Gall Bladder Cancer | — | UNRESOLVED | — |
| Hepatectomy | — | UNRESOLVED | — |
| Hepatopancreaticobiliary (HPB) Malignancy | — | UNRESOLVED | — |
| Pancreatoduodenectomy | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Hepatopancreatoduodenectomy | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- label
- GB cancer
- description
- Patients who were diagnosed with gallbladder cancer and underwent the hepatopancreatoduodenectomy.
- interventionNames
- Other: Hepatopancreatoduodenectomy
- label
- CCA
- description
- Patients who were diagnosed with cholangiocarcinoma and underwent the hepatopancreatoduodenectomy.
- interventionNames
- Other: Hepatopancreatoduodenectomy
Primary outcomes (2)
- measure
- 5-year overall survival
- timeFrame
- assessed up to 60months
- description
- the time from the date of surgery to the date of death or last follow-up.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 19 Years
Show eligibility criteria text
Inclusion Criteria: * Patients who received hepatopancreatoduodenectomy between January 2000 and December 2023. Exclusion Criteria: * Patients who had R2 resection
References
Publications (0)
Data not yet available